A methodology to assess the population size and estimate the needed resources for new licensed medications by combining clinical and administrative databases: the example of glycated haemoglobin in Type 2 Diabetes.

With this methodology, healthcare authorities should be able to quantify the population eligible to a new licensed medication, such as SGLT-2 inhibitors, and to simulate scenarios to assess reimbursement criteria according to precise estimates. This article is protected by copyright. All rights reserved.